Background In an analysis of the primary outcome of this phase 3 trial, patients with early
relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), …

Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells
is limited by antigen modulation, which may be overcome with combinatorial targeting. …

By increasing disease‐free survival and offering the potential for long‐term cure, chimeric
antigen receptor (CAR) T‐cell therapy has dramatically expanded therapeutic options among …

Background Glioblastoma (GBM) is refractory to immune checkpoint inhibitor (ICI) therapy.
We sought to determine to what extent this immune evasion is due to intrinsic properties of the …

Infections are a known complication of chimeric antigen receptor (CAR) T-cell therapy with
data largely emerging from CD19 CAR T-cell targeting. As CAR T-cell therapy continues to …

Immunotherapeutic strategies targeting B-cell acute lymphoblastic leukemia (B-ALL)
effectively induce remission; however, disease recurrence remains a challenge. Due to the …

As germline genetic testing capacities have improved over the last two decades, increasingly
more people are newly diagnosed with germline cancer susceptibility mutations. In the …

Axicabtagene ciloleucel (axi‐cel) in trials has demonstrated favorable efficacy compared
with historical controls after ≥2 lines of therapy for the treatment of relapsed or refractory (R/R) …

Screening electrocardiograms (EKGs) for attention deficit hyperactivity disorder (ADHD)
medication administration is controversial. We reviewed our experience as a community-based …

Introduction: Historically, older patients (pts) with relapsed/refractory large B-cell lymphoma (R/R
LBCL) were often deemed ineligible for curative-intent autologous stem cell transplant (…